COVAC-2
/ University of Saskatchewan
- LARVOL DELTA
Home
Next
Prev
1 to 19
Of
19
Go to page
1
September 17, 2025
Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.
(PubMed, Vaccine)
- "This Phase 1 trial indicated that COVAC-2 is safe and induces high levels of both antigen-specific binding and neutralizing antibodies by Day 42-56 with levels beginning to wane by Day 120."
First-in-human • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases • IFNG • IL5
May 03, 2024
Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: University of Saskatchewan | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 02, 2024
A Clinical Trial of COVAC-2 in Adults
(clinicaltrials.gov)
- P2 | N=150 | Completed | Sponsor: University of Saskatchewan | Active, not recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Mar 2024
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 19, 2023
Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: University of Saskatchewan | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 19, 2023
A Clinical Trial of COVAC-2 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=61 | Completed | Sponsor: University of Saskatchewan | Active, not recruiting ➔ Completed | Trial completion date: Apr 2023 ➔ Nov 2022
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 24, 2023
A Clinical Trial of COVAC-2 in Adults
(clinicaltrials.gov)
- P2 | N=150 | Active, not recruiting | Sponsor: University of Saskatchewan | Recruiting ➔ Active, not recruiting | N=300 ➔ 150 | Trial completion date: Aug 2023 ➔ Aug 2024 | Trial primary completion date: May 2023 ➔ Feb 2024
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 24, 2023
Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: University of Saskatchewan | Phase classification: P1/2 ➔ P1 | N=380 ➔ 60
Enrollment change • Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 31, 2022
A Clinical Trial of COVAC-2 in Adults
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: University of Saskatchewan | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 29, 2022
Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.
(clinicaltrials.gov)
- P1/2 | N=380 | Recruiting | Sponsor: University of Saskatchewan | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 08, 2022
A Clinical Trial of COVAC-2 in Adults
(clinicaltrials.gov)
- P2 | N=300 | Not yet recruiting | Sponsor: University of Saskatchewan | Initiation date: Jun 2022 ➔ Sep 2022
Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 08, 2022
A Clinical Trial of COVAC-2 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=72 | Active, not recruiting | Sponsor: University of Saskatchewan | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 17, 2022
Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.
(clinicaltrials.gov)
- P1/2 | N=380 | Not yet recruiting | Sponsor: University of Saskatchewan | Initiation date: Mar 2022 ➔ Jun 2022
Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 17, 2022
A Clinical Trial of COVAC-2 in Adults
(clinicaltrials.gov)
- P2 | N=300 | Not yet recruiting | Sponsor: University of Saskatchewan | Initiation date: Feb 2022 ➔ Jun 2022
Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
February 07, 2022
Clinical Trial to Study the COVAC-2 Booster Dose in Generally Healthy Adults.
(clinicaltrials.gov)
- P1/2 | N=380 | Not yet recruiting | Sponsor: University of Saskatchewan
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 26, 2022
A Clinical Trial of COVAC-2 in Adults
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: University of Saskatchewan
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
July 06, 2021
A Clinical Trial of COVAC-2 in Healthy Adults
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: University of Saskatchewan; N=108 ➔ 72
Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 01, 2021
A Clinical Trial of COVAC-2 in Healthy Adults
(clinicaltrials.gov)
- P1; N=108; Recruiting; Sponsor: University of Saskatchewan; Phase classification: P1/2 ➔ P1
Phase classification • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 29, 2021
A Clinical Trial of COVAC Vaccines in Healthy Adults
(clinicaltrials.gov)
- P1/2; N=108; Recruiting; Sponsor: University of Saskatchewan; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 08, 2021
A Clinical Trial of COVAC Vaccines in Healthy Adults
(clinicaltrials.gov)
- P1/2; N=108; Not yet recruiting; Sponsor: University of Saskatchewan
Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 19
Of
19
Go to page
1